Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average – Should You Sell?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.73 and traded as low as $12.61. Enanta Pharmaceuticals shares last traded at $13.14, with a volume of 112,824 shares.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ENTA shares. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Stock Up 1.3%

The firm has a market cap of $381.32 million, a P/E ratio of -4.11 and a beta of 0.99. The firm’s 50-day simple moving average is $13.43 and its 200 day simple moving average is $12.73.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. As a group, analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Commodore Capital LP bought a new stake in Enanta Pharmaceuticals during the 3rd quarter worth approximately $9,576,000. China Universal Asset Management Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 103.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 4,454 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $226,000. Stonepine Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 2.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 604,066 shares of the biotechnology company’s stock valued at $4,567,000 after purchasing an additional 13,324 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Enanta Pharmaceuticals during the third quarter worth about $133,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.